Literature DB >> 22188545

High concentrations of circulating interleukin-6 and monocyte chemotactic protein-1 with low concentrations of interleukin-8 were associated with severe chikungunya fever during the 2009-2010 outbreak in Thailand.

Jindarat Lohachanakul1, Weerawat Phuklia, Montri Thannagith, Tipparat Thonsakulprasert, Sukathida Ubol.   

Abstract

The recent outbreak of Chikungunya virus in Thailand caused a rheumatic fever associated with considerable morbidity and fatalities. Thus, it is important to identify biomarker(s) of severe disease induced by this threatening arbovirus. Putative biomarkers in cases of chikungunya fever during an outbreak in the southern part of Thailand in 2009-2010 were identified. Sixty-two patients who had developed fever and myalgia, with or without arthralgia/arthritis, were enrolled and grouped into severe chikungunya fever (CHIKF) (n= 15), mild CHIKF (n= 20) and non-CHIKF (n= 27) to investigate circulating immunological mediators that might serve as markers of severity. Blood samples were taken at presentation (day 1) and 30 days later (day 30) and plasma concentrations of interleukin (IL)-1β, IL-6, IL-8, IL-17, tumor necrosis factor-alpha, monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-1, tissue inhibitor of matrix metalloproteinase-1 and viral load were measured by ELISA. On day 1, severe CHIKF and mild CHIKF groups had viral loads of 10(8.5) and 10(8.3) of RNA copies/mL, respectively. At presentation, all CHIKF patients had circulating concentrations of IL-6 and MCP-1 higher than did non-CHIKF patients, whereas amongst the CHKF patients, the severe CHIKF patients had higher IL-6 concentrations than did mild CHIKF patients. Interestingly, severe CHIKF patients had significantly lower concentrations of circulating IL-8 than the other groups of patients, suggesting that high concentrations of IL-6 and MCP-1 with low concentrations of IL-8 may be a determinant of severe chikungunya virus infection.
© 2012 The Societies and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22188545     DOI: 10.1111/j.1348-0421.2011.00417.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  20 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

Review 2.  Chikungunya in the region of the Americas. A challenge for rheumatologists and health care systems.

Authors:  Carlos Pineda; Roberto Muñoz-Louis; Carlo V Caballero-Uribe; Diego Viasus
Journal:  Clin Rheumatol       Date:  2016-08-24       Impact factor: 2.980

3.  IL-18: a suggested target for immunomodulation in chikungunya virus infection.

Authors:  Chintana Chirathaworn; Jira Chansaenroj; Pornsuri Pongsuchart; Yong Poovorawan
Journal:  Arch Virol       Date:  2020-10-19       Impact factor: 2.574

4.  Mechanisms underlying the pathogenesis of arthritogenic alphaviruses: host immune responses and virus persistence.

Authors:  David W Hawman; Kristina S Burrack; Thomas E Morrison
Journal:  Future Virol       Date:  2014-06-16       Impact factor: 1.831

5.  Comprehensive proteomic analysis of white blood cells from chikungunya fever patients of different severities.

Authors:  Nitwara Wikan; Sarawut Khongwichit; Weerawat Phuklia; Sukathida Ubol; Tipparat Thonsakulprasert; Montri Thannagith; Duangrudee Tanramluk; Atchara Paemanee; Suthathip Kittisenachai; Sittiruk Roytrakul; Duncan R Smith
Journal:  J Transl Med       Date:  2014-04-11       Impact factor: 5.531

6.  Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss.

Authors:  Weiqiang Chen; Suan-Sin Foo; Nestor E Rulli; Adam Taylor; Kuo-Ching Sheng; Lara J Herrero; Belinda L Herring; Brett A Lidbury; Rachel W Li; Nicole C Walsh; Natalie A Sims; Paul N Smith; Suresh Mahalingam
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

7.  Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).

Authors:  Ashley Dagley; Jane Ennis; Jeffrey D Turner; Kerry A Rood; Arnaud J Van Wettere; Brian B Gowen; Justin G Julander
Journal:  Antiviral Res       Date:  2014-05-14       Impact factor: 5.970

8.  A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection.

Authors:  Terk-Shin Teng; Yiu-Wing Kam; Bernett Lee; Hapuarachchige Chanditha Hapuarachchi; Abeyewickreme Wimal; Lee-Ching Ng; Lisa F P Ng
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

9.  Proteomic profiling of serum samples from chikungunya-infected patients provides insights into host response.

Authors:  Vinuth N Puttamallesh; Sreelakshmi K Sreenivasamurthy; Pradeep Kumar Singh; H C Harsha; Anjali Ganjiwale; Shobha Broor; Akhilesh Pandey; Jayasuryan Narayana; T S Keshava Prasad
Journal:  Clin Proteomics       Date:  2013-10-14       Impact factor: 3.988

10.  Inflammatory biomarkers, disease activity index, and self-reported disability may be predictors of chronic arthritis after chikungunya infection: brief report.

Authors:  J Sepúlveda-Delgado; O L Vera-Lastra; K Trujillo-Murillo; L M Canseco-Ávila; R A Sánchez-González; O Gómez-Cruz; A Lugo-Trampe; I Fernández-Salas; R Danis-Lozano; A Contreras-Contreras; A Mendoza-Torres; S Domínguez-Arrevillaga; B A Mena-Vela; M Ocaña-Sibilla; J C Ramirez-Valdespino; L J Jara
Journal:  Clin Rheumatol       Date:  2016-09-28       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.